We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Califf Faces Questions Over Ties to Industry at Confirmation Hearing

Califf Faces Questions Over Ties to Industry at Confirmation Hearing

November 23, 2015

The majority of the Senate Committee on Health, Education, Labor and Pensions, from both sides of the aisle, expressed support for Robert Califf’s nomination as the next FDA commissioner last week.

HELP Committee Chairman Sen. Lamar Alexander (R–Tenn.) called Califf’s qualifications “impressive,” and Sen. Patty Murray (D–Wash.) said he is a “strong nominee” with an impressive resume and a longstanding commitment to transparency, and encouraged her colleagues to vote for him.

Interestingly, the sharpest criticism of President Barack Obama’s nomination came from his own party. Democratic presidential nominee Sen. Bernie Sanders (I-Vt.), who already has said he does not support Califf because of his cozy relationship with the pharmaceutical industry, prefaced his line of questioning with a statement of disapproval.

The senator repeatedly questioned why the FDA permits the importation of seafood from all over the world but will not allow the importation of lower-cost brand name drugs from countries like Canada. Califf said that the FDA has major concerns about reimported drug products and allowing them would incur huge costs to the agency.

Califf asserted that it is not the FDA’s job to set drug prices, but Sanders wouldn’t have it, saying that it is well within the agency’s jurisdiction. “We need a commissioner who is going to stand up to the pharmaceutical industry,” Sanders told Califf, “and I don’t believe that you are that person.”

Sen. Elizabeth Warren (D–Mass.) also had some tough questions for Califf — particularly over whether he would lower the standards for approval of drugs. Califf maintained that he is “not a proponent of lowering standards for anything.” This answer did not seem to satisfy Warren, who promised that she would not vote on his nomination until she read all of Duke University’s contracts with industry during his time there overseeing clinical trials.

Despite his nomination being widely praised by stakeholders, some groups — including Public Citizen — have questioned his closeness to industry because of the clinical trials he helped conduct.

Califf hammered home his trial program’s independence, saying that although some studies are funded by industry, “ironclad” contracts and international steering committees guaranteed the right to run trials freely. Industry could not influence the data or change what researchers said about trials, Califf added.

Califf also claimed that he donated any money he received as a consultant to nonprofit charities.

Sen. Bill Cassidy (R–La.) asked if greater advantage could be taken of compounding pharmacies to make drugs available more quickly instead of the generic route. For example, a generic of Turing’s Daraprim (pyrimethamine) — which has received negative attention because the drugmaker tried to drive up the decades-old product’s price — is years away; however, it has been made available for as low as $1 a pill through compounders, Cassidy said. Califf noted that this example can’t result in uniform change, as every drug is different, and the FDA is working hard on standards for compounders.

One avenue to drive down drug prices is seeking ways to lower clinical trial costs, Califf said. He added that the FDA is committed to working with industry and academia to develop a system that delivers better clinical trial results with a larger, more representative population, at a dramatically lower cost. That can be done, Califf said, by taking better advantage of electronic health records.

Labeling of biosimilars is also a high priority for the FDA, he told the committee. Labels should encourage their use, but they also should let patients and prescribers know that they’re different from the reference product. Labeling also needs to include global standards for nomenclature so that the products can be tracked in the marketplace, he said.

Finally, Califf opined that another regulatory pathway is needed for combination products, adding that within the next year, the FDA hopes it can present its opinions and work with Congress to develop the “right balance” for potential regulations.

Pharmaceuticals Regulatory Affairs
  • Related Events

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Thermo Fisher Scientific Gets FDA Premarket Approval for Companion Diagnostic

  • MHRA Grants Conditional Authorization to Moderna’s Bivalent COVID-19 Booster Vaccine

  • Organogenesis Gets 510(k) Clearance to Expand PuraPly Portfolio

  • FDA Grants Priority Review to sNDA for Lynparza

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing